期刊文献+

胰腺癌组织生长抑素受体mRNA的表达及意义

Expression of Somatostatin Receptor mRNA in Human Pancreatic Cancer and Its Signification
下载PDF
导出
摘要 目的 研究人体胰腺癌组织生长抑素受体mRNA的表达。方法 应用逆转录PCR(RT-PCR)检测30例胰腺癌组织和12例正常胰腺组织生长抑素受体亚型mRNA的表达。结果 (1)胰腺癌生长抑素受体5种亚型SSTR1~5mRNA表达依次为2,29±0.87,3,72±1.42,1,91±0.92,1.80±0.98,2.25±0.92,其中SSTR2mRNA表达明显高于其他亚型(P〈0.01)。(2)正常胰腺组织SSTR1~5mRNA表达依次为1.37±0.74,1.38±0.98,1.26±0.79,1.21±0.42,1.33±0.92,各亚型mRNA表达比较无显著性差异(P〉0.05)。(3)胰腺癌SsTR1·2·5mRNA表达明显高于正常胰腺组织的相应亚型(P〈0.01),SSTR3mRNA表达也明显高于正常胰腺组织(P〈0.05)。结论 胰腺癌组织SSTR1·2·3·5mRNA表达水平明显高于正常胰腺组织,并且胰腺癌以SSTR2mRNA表达最为显著。 Objective To investigate the expression of somatostatin receptor(SSTR)mRNA in human pancreatic cancer. Methods The expression of SSTR subtype 1 - 5 mRNA was determined by reverse transcription polymerase chain reaction method in 30 cases of pancreatic cancer and in 12 cases of normal pancreas tissues. Results (1) The expression of SSTR 1- 5 mRNA in pancreatic cancer was 2.29 ± 0.87, 3.72±1.42, 1.91 ±0.92, 1.80 ± 0.98 and 2.25± 0.92. The expression of SSTR2 mRNA was significantly higher than the expression of SSTR1·3· 4·5mRNA( P 〈 0.01). (2) The expression of SSTR 1- 5 mRNA in normal pancreas tissues was 1.37 ±0.74, 1.38±0.98, 1.26 ±0.79, 1.21± 0.42 and 1.33± 0.92 respectively. There was no significant difference between the expression of SSTR 1-5 mRNA( P 〉 0.05). (3) The expression of SSTR1·2· 5 mRNA in pancreatic cancer was significantly higher than those in the normal pancreas tissues( P 〈 0.01). The expression of SSTR3 mRNA was showed also in this way ( P 〈 0.05). Conclusions The expression of SSTR1·2· 3· 5mRNA in pancreatic cancer is significantly higher than those in the'normal pancreas tissues. The expression of SSTR2 mRNA is significantly higher than that of SSTR1·3· 4· 5mRNA in pancreatic cancer.
出处 《苏州大学学报(医学版)》 CAS 北大核心 2006年第5期798-801,共4页 Suzhou University Journal of Medical Science
关键词 胰腺癌 生长抑素受体 逆转录PCR pancreatic cancer somatostatin receptor reverse transcription polymerase chain reaction
  • 相关文献

参考文献11

  • 1Reubi JC,Schaer JC,Markwalder R,et al.Distribution of somatostatin receptors in normal and neoplastic human tissues:recent advances and potential relevance[J].Yale J Bio Med,1997,70:471-479.
  • 2Maria C Zatelli,Federico Tagliati,John E Taylor,et al.Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line[J].J Clin Endocrinol Metab,2001,86:2161-2169.
  • 3Hawes RH,Xiong Q,Waxman I,et al.A multispecialty approach to the diagnosis and management of pancreatic cancer[J].Am J Gastroenterol,2000,95:17-31.
  • 4Arnaldi G,Mancini T,Kola B,et al.Cyclical Cushing's syndrome in a patient with a bronchial neuroendocrine tumor(typical carcinoid) expressing ghrelin and growth hormone secretagogue receptors[J].J Clin Endocrinol Metab,2003,88:5834-5840.
  • 5Duet M,Sauvaget E,Petelle B,et al.Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck[J].J Nucl Med,2003,44:1767-1774.
  • 6Bertherat J,Tenenbaum F,Perlemoine K,et al.Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas:an in vivo and in vitro study[J].J Clin Endocrinol Metab,2003,88:5353-5360.
  • 7Blum JE,Handmarker H,Rinne NA.The utility of a somatostatin-type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules[J].Chest,1999,115:224-232.
  • 8季沅,李建平,王自正,王峰,张志德.胰腺癌生长抑素受体^(99m)Tc-Sandostatin 显像的实验研究[J].中华肝胆外科杂志,2006,12(2):131-132. 被引量:1
  • 9Pawlikowski M,Melen-Mucha G.Perspectives of new potential therapeutic applications of somatostatin analogs[J].Neuroendocrinol Lett,2003,24:21-27.
  • 10Fisher WE,Muscarella P,O' Dorisio TM,et al.Expression of the somatostatin recepts subtype 2 genes predicts response of human pancreatic cancer to octreotide[J].Surgery,1996,120:234-241.

二级参考文献3

  • 1Gotthardt M,Behe MP,Alfke H,et al.Imaging lung tumors with peptide-based radioligands.Clin Lung Cancer,2003,5:119-124.
  • 2Decristoforo C,Mather SJ,Cholewinski W,et al.^99mTc-EDDA/HYNIC -TOC:a new ^99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours:first clinical results and intra-patient comparison with ^111In-labelled octreotide derivatives.Eur J Nucl Med,2000,27:1319-1325.
  • 3Gabriel M,Decristoforo C,Donnemiller E,et al.An intrapatient comparison of ^99mTc-EDDA/HYNIC-TOC With ^111In-DTPA-Octreotide for diagnosis of somatostatin receptor-expressing tumors.J Nucl Med,2003,44:708-716.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部